Key result
18F-FDG-PET/CT demonstrated a sensitivity of 96% compared to 76% for CT in staging marginal zone B cell lymphoma, and provided a 100% negative predictive value for post-treatment response.
Why the study?
Does 18F-FDG-PET/CT improve staging and response assessment compared to CT in patients with marginal zone B cell lymphoma?
Population
25 consecutive patients with marginal zone B cell lymphoma (MZL)
Comparison
18F-FDG-PET/CT for staging and first-line… vs CT (computed tomography)
Design
Cohort
Follow-up
median 50 months (10-152 months)
Authors
Loading...
May support PET/CT consideration for marginal zone lymphoma staging; leaves open prospective validation of outcome impact.
Observational (n=25)
Does 18F-FDG-PET/CT improve staging and response assessment compared to CT in patients with marginal zone B cell lymphoma?
Absolute Event Rate: 96% vs 76%
18F-FDG-PET/CT demonstrates higher sensitivity than CT for staging and response assessment in marginal zone B cell lymphoma, potentially impacting clinical management.
Carrillo‐Cruz et al. (2014) conducted an observational in Marginal zone B cell lymphoma (MZL) (n=25). 18F-FDG-PET/CT vs. CT was evaluated on Sensitivity for staging. 18F-FDG-PET/CT demonstrated a sensitivity of 96% compared to 76% for CT in staging marginal zone B cell lymphoma, and provided a 100% negative predictive value for post-treatment response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: